Department of Medical Nursing, School of Nursing, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Syst Rev. 2023 Nov 13;12(1):212. doi: 10.1186/s13643-023-02377-0.
Acute respiratory distress syndrome (ARDS) is potentially a fatal form of respiratory failure among COVID-19 patients. Globally, there are inconsistent findings regarding ARDS among COVID-19 patients. Therefore, this study aimed to estimate the pooled prevalence of COVID-19-induced ARDS among COVID-19 patients worldwide.
To retrieve relevant studies, the authors searched Embase, MEDLINE, PubMed, Web of Science, Cochrane Library, Google, and Google Scholar using a combination of search terms. The search was conducted for articles published from December 2019 to September 2022. Articles were searched and screened by title (ti), abstract (ab), and full-text (ft) by two reviewers independently. The quality of each included article was assessed using the Newcastle-Ottawa Assessment Scale. Data were entered into Microsoft Word and exported to Stata version 14 for analysis. Heterogeneity was detected using the Cochrane Q statistics and I-square (I). Then the sources of variations were identified by subgroup and meta-regression analysis. A random effect meta-analysis model was used. The publication bias was detected using the graphic asymmetry test of the funnel plot and/or Egger's test (p value < 0.05). To treat the potential publication bias, trim and fill analysis were computed. The protocol has been registered in an international database, the Prospective Register of Systematic Reviews (PROSPERO) with reference number: CRD42023438277.
A total of 794 studies worldwide were screened for their eligibility. Of these 11 studies with 2845 participants were included in this systematic review and meta-analysis. The overall pooled prevalence of COVID-19-induced ARDS in the world was found to be 32.2% (95%CI = 27.70-41.73%), I = 97.3%, and p value < 0.001).
The pooled prevalence of COVID-19-induced ARDS was found to be high. The virus remains a global burden because its genetic causes are constantly changing or it mutated throughout the pandemic to emerge a new strain of infection. Therefore, interventions such as massive vaccination, early case detection, screening, isolation, and treatment of the cases need to be implemented to tackle its severity.
急性呼吸窘迫综合征（ARDS）是 COVID-19 患者潜在的致命性呼吸衰竭形式。在全球范围内，关于 COVID-19 患者的 ARDS 存在不一致的发现。因此，本研究旨在估计全球 COVID-19 患者中 COVID-19 诱导的 ARDS 的汇总患病率。
为了检索相关研究，作者使用组合搜索词在 Embase、MEDLINE、PubMed、Web of Science、Cochrane 图书馆、Google 和 Google Scholar 中进行了搜索。搜索范围为 2019 年 12 月至 2022 年 9 月发表的文章。两位审稿人分别通过标题（ti）、摘要（ab）和全文（ft）对文章进行了搜索和筛选。使用纽卡斯尔-渥太华评估量表评估每篇纳入文章的质量。将数据输入 Microsoft Word 并导出到 Stata 版本 14 进行分析。使用 Cochrane Q 统计量和 I 平方（I）检测异质性。然后通过亚组和荟萃回归分析确定变异源。使用随机效应荟萃分析模型。使用漏斗图的图形不对称检验和/或 Egger 检验（p 值<0.05）检测发表偏倚。为了处理潜在的发表偏倚，计算了修剪和填充分析。该方案已在国际数据库中注册，前瞻性系统评价注册处（PROSPERO），参考编号：CRD42023438277。
全球范围内共筛选了 794 项研究以确定其纳入资格。其中，有 11 项研究共纳入 2845 名参与者纳入本系统评价和荟萃分析。发现全球 COVID-19 诱导的 ARDS 的总体汇总患病率为 32.2%（95%CI=27.70-41.73%），I=97.3%，p 值<0.001）。
发现 COVID-19 诱导的 ARDS 的患病率很高。由于其遗传原因不断变化，或者在大流行期间发生突变而出现新的感染株，该病毒仍然是全球的负担。因此，需要实施大规模接种疫苗、早期病例发现、筛查、隔离和治疗等干预措施，以应对其严重程度。
Zotero 插件
